These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 19911471)
21. Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial. Bussmann H; Wester CW; Thomas A; Novitsky V; Okezie R; Muzenda T; Gaolathe T; Ndwapi N; Mawoko N; Widenfelt E; Moyo S; Musonda R; Mine M; Makhema J; Moffat H; Essex M; Degruttola V; Marlink RG J Acquir Immune Defic Syndr; 2009 May; 51(1):37-46. PubMed ID: 19282782 [TBL] [Abstract][Full Text] [Related]
22. Subclinical atherosclerosis among HIV-infected adults attending HIV/AIDS care at two large ambulatory HIV clinics in Uganda. Ssinabulya I; Kayima J; Longenecker C; Luwedde M; Semitala F; Kambugu A; Ameda F; Bugeza S; McComsey G; Freers J; Nakanjako D PLoS One; 2014; 9(2):e89537. PubMed ID: 24586854 [TBL] [Abstract][Full Text] [Related]
23. Nutritional Status and Lipid Profile in HIV-Infected Adults. Stambullian M; Feliu MS; Cassetti LI; Slobodianik NH Endocr Metab Immune Disord Drug Targets; 2015; 15(4):302-7. PubMed ID: 26343060 [TBL] [Abstract][Full Text] [Related]
24. HIV infection, antiretroviral therapy initiation and longitudinal changes in biomarkers of organ function. So-Armah KA; Chang J; Alcorn C; Lo Re V; Baker JV; Tracy R; Butt AA; Agan BK; Rimland D; Gibert CL; Goetz MB; Oursler KK; Rodriguez-Barradas MC; Kuller LH; Brown ST; Stein JH; Skanderson M; Justice AC; Freiberg MS Curr HIV Res; 2014; 12(1):50-9. PubMed ID: 25034208 [TBL] [Abstract][Full Text] [Related]
25. Increased carotid intima media thickness and cardiac biomarkers in HIV infected children. McComsey GA; O'Riordan M; Hazen SL; El-Bejjani D; Bhatt S; Brennan ML; Storer N; Adell J; Nakamoto DA; Dogra V AIDS; 2007 May; 21(8):921-7. PubMed ID: 17457085 [TBL] [Abstract][Full Text] [Related]
26. Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study. Achhra AC; Mocroft A; Reiss P; Sabin C; Ryom L; de Wit S; Smith CJ; d'Arminio Monforte A; Phillips A; Weber R; Lundgren J; Law MG; HIV Med; 2016 Apr; 17(4):255-68. PubMed ID: 26216031 [TBL] [Abstract][Full Text] [Related]
27. Presence of the metabolic syndrome is not a better predictor of cardiovascular disease than the sum of its components in HIV-infected individuals: data collection on adverse events of anti-HIV drugs (D:A:D) study. Worm SW; Sabin CA; Reiss P; El-Sadr W; Monforte Ad; Pradier C; Thiebaut R; Law M; Rickenbach M; De Wit S; Lundgren JD; Friis-Møller N Diabetes Care; 2009 Mar; 32(3):474-80. PubMed ID: 19056612 [TBL] [Abstract][Full Text] [Related]
28. Cardiovascular risk prediction in HIV-infected patients: comparing the Framingham, atherosclerotic cardiovascular disease risk score (ASCVD), Systematic Coronary Risk Evaluation for the Netherlands (SCORE-NL) and Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) risk prediction models. Krikke M; Hoogeveen RC; Hoepelman AI; Visseren FL; Arends JE HIV Med; 2016 Apr; 17(4):289-97. PubMed ID: 26268806 [TBL] [Abstract][Full Text] [Related]
29. C-reactive protein: a poor marker of cardiovascular disease risk in HIV+ populations with a high prevalence of elevated serum transaminases. Baum MK; Rafie C; Sales S; Lai S; Duan R; Jayaweera DT; Page JB; Campa A Int J STD AIDS; 2008 Jun; 19(6):410-3. PubMed ID: 18595880 [TBL] [Abstract][Full Text] [Related]
30. The burden of hypertension, diabetes mellitus, and cardiovascular risk factors among adult Malawians in HIV care: consequences for integrated services. Divala OH; Amberbir A; Ismail Z; Beyene T; Garone D; Pfaff C; Singano V; Akello H; Joshua M; Nyirenda MJ; Matengeni A; Berman J; Mallewa J; Chinomba GS; Kayange N; Allain TJ; Chan AK; Sodhi SK; van Oosterhout JJ BMC Public Health; 2016 Dec; 16(1):1243. PubMed ID: 27955664 [TBL] [Abstract][Full Text] [Related]
31. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study. McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A; Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284 [TBL] [Abstract][Full Text] [Related]
32. Impact of prolonged maraviroc treatment on non-AIDS-related comorbidities in HIV-positive patients: a retrospective cohort study. Piconi S; Foschi A; Malagoli A; Carli F; Zona S; Milic J; Ricci ED; Rizzardini G; Guaraldi G J Antimicrob Chemother; 2019 Sep; 74(9):2723-2731. PubMed ID: 31139818 [TBL] [Abstract][Full Text] [Related]
33. Improved measures of quality of life, lipid profile, and lipoatrophy after treatment interruption in HIV-infected patients with immune preservation: results of ACTG 5170. Skiest DJ; Krambrink A; Su Z; Robertson KR; Margolis DM; J Acquir Immune Defic Syndr; 2008 Dec; 49(4):377-83. PubMed ID: 18931631 [TBL] [Abstract][Full Text] [Related]
34. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus. Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112 [TBL] [Abstract][Full Text] [Related]
35. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV. Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD008270. PubMed ID: 23740608 [TBL] [Abstract][Full Text] [Related]